US › Healthcare

20/20 Biolabs, Inc. Common Stock (AIDX)

US · Healthcare · Medical Devices

$0.47-1.93%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$730,571

Revenue YoY

+36.5%

Net profit

$-1.5M

EPS

$-0.26

EPS estimate

$-0.12

Net margin

-206.2%

EPS came in at -0.26 against a street estimate of -0.12 — a miss of 116.7%.

Key statistics

Market cap

$7.2M

Forward P/E

0.0

P/B

4.33

Book value

$0.13

EPS (TTM)

$-0.58

52-week high

$50.00

52-week low

$0.40

50-day MA

$0.53

200-day MA

$1.60

Beta

-0.42

Analyst view

with an average price target of $5.00.

Shareholding

Insiders

25.09%

Institutions

4.23%

Largest institutional holders

Fund	Stake
Cresset Asset Management, LLC	2.16%
Atlantic Union Bankshares Corp	0.29%
Citadel Advisors Llc	0.19%
XTX Topco Ltd	0.08%
UBS Group AG	0.07%
McDonald Partners, LLC	0.02%
Mccormack Advisors International	0.01%
Toth Financial Advisory Corp	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for 20/20 Biolabs, Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.